Soft tissue tumors include neoplasms of specific and unknown lineages, and,
therefore, lineage markers of smooth muscle, skeletal muscle, endothelial,
epithelial and Schwann cells have proven useful in everyday practice. Howe
ver, groups of tumors remain that are defined essentially on grounds of his
tology; others can be defined by molecular genetic studies. The complex dis
tribution patterns of many antigens, and loss of some differentiation antig
ens in malignant tumors often necessitate the use of panels of antibodies.
Optimally such panels should address all significant differential diagnosti
c alternatives. There is little doubt that numerous new differentiation mar
kers will appear in the future. The evaluation of tumor proliferation, apop
tosis, and cell cycle control will give new information related to tumor bi
ology and prognosis.